Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Articles tagged with "Osteoporosis"

Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

Will Boggs MD  |  

NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials. “These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University…

Hip Fractures Increasing in Older U.S. Women

Cheryl Platzman Weinstock  |  

(Reuters Health)—The incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients. Hip fracture rates declined each year from 2002–2012, the researchers found. But starting in 2013, hip fracture rates leveled off and were higher than expected….

Vitamin D, Calcium Supplements May Not Lower Fracture Risk

Lisa Rapaport  |  

(Reuters Health)—Older adults who take vitamin D and calcium are no less likely to break their hips or other bones than peers who don’t use these supplements, a research review suggests. Researchers examined data from 33 previous trials with a total of more than 51,000 people aged 50 or older who were living in the…

Rheumatology Drug Updates: Hip Fracture Rates After Bisphosphonate Drug Holidays, Plus More on Golimumab, Ustekinumab

  |  

Bisphosphonate Drug Holidays Drug holidays are common for patients on bisphosphonate therapy. Often, these breaks in treatment are related to known U.S. Food and Drug Administration (FDA) warnings and drug class adverse effects. Currently, data on fracture risk related to drug holidays are limited. In recent research highlighted at the 2017 ACR/ARHP Annual Meeting ,…

SIRT1: A Therapeutic Target for Osteoporosis?

  |  

New research has found the sirtuin family of proteins may be a positive regulator of bone mass. In the study, pharmacological activation of SIRT1 in mice resulted in increased bone mass, suggesting the pharmacological activation of SIRT1 may protect against osteoporosis…

Bisphosphonates May Limit Fracture Risk in Users of Oral Glucocorticoids

Reuters Staff  |  

NEW YORK (Reuters Health)—Early oral bisphosphonate use is associated with a lower risk of fractures among oral-glucocorticoid users, researchers from Canada report. Bisphosphonates are commonly used for glucocorticoid-induced osteoporosis, but their efficacy has been established only in primary osteoporosis, where the mechanism of action of bone loss differs from that seen with glucocorticoid use. Dr….

Rheumatologist’s Passion for Gardening Keeps Plants, Patients Healthy

  |  

Deborah Dyett Desir, MD, vividly remembers her first day as an undergraduate student at Harvard University, Boston. When her parents helped her move into the dorm, her mother, Betty, handed her a beautiful begonia. “My response was, ‘What on earth am I going to do with this plant?’” she says, recalling how she examined the…

Letter: Tips to Improve Osteoporosis Screening Rates

Timothy Harrington, MD  |  

Osteoporosis Screening The aphorism, “Those who do not learn history are doomed to repeat it,” applies to The Rheumatologist August 2017 article that documents the continued low screening rates for those at high risk for osteoporosis-related fragility fractures, in particular people older than 65 and those who have suffered a fracture already. So here’s a…